NV5 Share Price Performance
€0.046
-0.02 (-34.34%)
Price €0.046
Share Price€0.046
We're Hopeful That AcuCort (BST:NV5) Will Use Its Cash Wisely
Aug 16
AcuCort AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
NV5 Community Narratives
There are no narratives available yet.
AcuCort AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.10
- Gross Margin
- -137.40%
- Net Profit Margin
- -301.13%
- Debt/Equity Ratio
- 0%
AcuCort AB (publ) Competitors
Snowflake Analysis
About NV5
- Founded
- 2006
- Employees
- 4
- CEO
- WebsiteView website
AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Swedish Market Performance
- 7 Days: 1.7%
- 3 Months: 2.4%
- 1 Year: -0.5%
- Year to Date: 2.9%
The market has climbed 1.7% in the last 7 days, lead by the Industrials sector with a gain of 2.6%. The market has been flat overall in the last year. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›